S Campbell Austin1, Luis Sanchez-Ramos, C David Adair. 1. Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, FL, USA. Campbell.Austin@jax.ufl.edu
Abstract
OBJECTIVE: The purpose of this study was to review randomized trials that compared the efficacy of the dinoprostone 10-mg controlled-release vaginal insert with that of vaginally administered misoprostol tablets in cervical ripening and labor induction. STUDY DESIGN: Electronic databases were used to identify randomized clinical trials that compared dinoprostone with misoprostol. Estimates of the relative risk for individual studies and risk difference from dichotomous outcomes with the use of random and fixed-effects models were calculated. RESULTS: Women who received misoprostol had a higher incidence of vaginal delivery within 12 and 24 hours of prostaglandin application, compared with dinoprostone. Both modalities had similar incidences of cesarean delivery, uterine hyperstimulation, and fetal tachysystole. There was an increased need for oxytocin augmentation in the dinoprostone group. No significant difference in neonatal outcomes was noted between the 2 groups. CONCLUSION: Vaginally administered misoprostol was more effective than the dinoprostone vaginal insert for cervical ripening and labor induction. The safety profiles of both drugs were similar. Copyright 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: The purpose of this study was to review randomized trials that compared the efficacy of the dinoprostone 10-mg controlled-release vaginal insert with that of vaginally administered misoprostol tablets in cervical ripening and labor induction. STUDY DESIGN: Electronic databases were used to identify randomized clinical trials that compared dinoprostone with misoprostol. Estimates of the relative risk for individual studies and risk difference from dichotomous outcomes with the use of random and fixed-effects models were calculated. RESULTS:Women who received misoprostol had a higher incidence of vaginal delivery within 12 and 24 hours of prostaglandin application, compared with dinoprostone. Both modalities had similar incidences of cesarean delivery, uterine hyperstimulation, and fetal tachysystole. There was an increased need for oxytocin augmentation in the dinoprostone group. No significant difference in neonatal outcomes was noted between the 2 groups. CONCLUSION: Vaginally administered misoprostol was more effective than the dinoprostone vaginal insert for cervical ripening and labor induction. The safety profiles of both drugs were similar. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Giuseppe Chioss; Maged M Costantine; Egle Bytautiene; Ancizar Betancourt; Gary D V Hankins; George R Saade; Monica Longo Journal: Am J Perinatol Date: 2012-05-29 Impact factor: 1.862
Authors: P Tsikouras; Z Koukouli; B Manav; M Soilemetzidis; A Liberis; R Csorba; G Trypsianis; G Galazios Journal: Geburtshilfe Frauenheilkd Date: 2016-07 Impact factor: 2.915
Authors: Giuseppe Chiossi; Maged M Costantine; Egle Bytautiene; Talar Kechichian; Gary D V Hankins; Elena Sbrana; George R Saade; Monica Longo Journal: Am J Perinatol Date: 2012-05-25 Impact factor: 1.862
Authors: Marco La Verde; Adriano Palmisano; Irene Iavarone; Carlo Ronsini; Domenico Labriola; Stefano Cianci; Ferdinando Schettino; Alfonso Reginelli; Gaetano Riemma; Pasquale De Franciscis Journal: Int J Environ Res Public Health Date: 2022-04-12 Impact factor: 4.614